Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-02-23FDA Approved: LOXAPINE — Supplemental Application (Elite Laboratories, Inc.)
The FDA approved a supplemental application for LOXAPINE submitted by Elite Laboratories, Inc., for this generic loxapine product. Loxapine …
-
FDA approval · 2017-02-23FDA Approved: MOLINDONE HYDROCHLORIDE — Supplemental Application (EPIC PHARMA, LLC)
The FDA approved a supplemental application for molindone hydrochloride, a generic antipsychotic, submitted by Epic Pharma, LLC.
-
FDA approval · 2017-02-23FDA Approved: INVEGA HAFYERA — Supplemental Application (Janssen Pharmaceuticals, Inc)
FDA approves Janssen's supplemental application for INVEGA HAFYERA (paliperidone palmitate), updating its labeling for schizophrenia in adul…
-
FDA approval · 2017-02-23FDA Approved: CHLORPROMAZINE HCI — Supplemental Application (Dr. Reddy's Laboratories Inc.,)
FDA approved a supplemental application for Chlorpromazine HCl by Dr. Reddy's Laboratories Inc., granting approval for a generic version of …
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Brexpiprazole in Patients With Schizophrenia [Phase 3]
Phase 3 clinical trial update showing results posting for brexpiprazole in adults with schizophrenia. The study (NCT01810783) has completed …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-02-23FDA Approved: ARIPIPRAZOLE — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for aripiprazole, enabling the generic version to be marketed.
-
FDA approval · 2017-02-23FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for Lannett's generic fluphenazine hydrochloride, enabling the sale of this antipsychotic as a g…
-
FDA approval · 2017-02-23FDA Approved: ARIPIPRAZOLE — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application to authorize a generic aripiprazole product by Lannett Company, Inc. under ANDA204171.
-
CLINICAL_TRIALS trial_result · 2017-02-17Clinical Trial Update: Cognitive Remediation Therapy in Schizophrenia: Effects on BDNF Levels [NA]
This update summarizes a completed trial evaluating cognitive remediation therapy in schizophrenia and its effect on Brain-Derived Neurotrop…
-
FDA approval · 2017-02-17FDA Approved: ZIPRASIDONE HYDROCHLORIDE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved Macleods Pharmaceuticals Limited's original application for ziprasidone hydrochloride, granting a generic version of ziprasidon…
-
CLINICAL_TRIALS research · 2017-02-16Clinical Trial Update: Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia [Phase 1, Phase 2]
A clinical trial update on the antipsychotic effects of JOBELYN, derived from Sorghum bicolor, in treating schizophrenia, conducted in Phase…
-
CLINICAL_TRIALS trial_result · 2017-02-16Clinical Trial Update: Arithmetic Training With the Kumon Method for Cognition in Schizophrenia [NA]
This is a completed clinical trial evaluating arithmetic training with the Kumon method to improve cognitive function in schizophrenia. The …
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia [Phase 1]
Phase 1 study assessing safety, tolerability, and pharmacokinetics of oral brexpiprazole (OPC-34712) in adolescents with schizophrenia has c…
-
CLINICAL_TRIALS trial_result · 2017-02-15Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia [Phase 3]
Phase 3 trial evaluating bitopertin for persistent, predominant negative symptoms of schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2017-02-10Clinical Trial Update: Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia [Phase 2]
Phase 2 clinical trial update on pregnenolone for cognitive and negative symptoms in schizophrenia and schizoaffective disorder. Results wer…
-
CLINICAL_TRIALS trial_result · 2017-02-09Clinical Trial Update: Conversion to Antipsychotic Monotherapy [NA]
The clinical trial NCT01368458 evaluating conversion to antipsychotic monotherapy in schizophrenia and schizoaffective disorder has been ter…
-
CLINICAL_TRIALS trial_result · 2017-02-08Clinical Trial Update: D-serine for the Schizophrenia Prodrome [Phase 2]
Phase 2 trial update showing results for D-serine in the schizophrenia prodrome; the study completed and results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-02-07Clinical Trial Update: Metformin for Weight Loss in Schizophrenia [NA]
A study evaluating metformin for weight loss in people with schizophrenia and obesity was terminated. Results were posted on 2017-02-07.
-
FDA approval · 2017-02-01FDA Approved: RISPERIDONE — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved a supplemental application for risperidone submitted by Ajanta Pharma USA Inc. The approval indicates updated labeling and pote…
-
FDA approval · 2017-02-01FDA Approved: ARIPIPRAZOLE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for aripiprazole (generic ARIPIPRAZOLE) from Amneal Pharmaceuticals LLC, authorizing the generic for…
-
CLINICAL_TRIALS trial_result · 2017-02-01Clinical Trial Update: Omega-3 Dietary Supplements in Schizophrenia [NA]
The clinical trial evaluating omega-3 dietary supplements for schizophrenia has completed and its results were posted in February 2017.
-
CLINICAL_TRIALS trial_result · 2017-01-31Clinical Trial Update: PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia [Phase 1]
Phase 1 trial assessing the pharmacokinetics, safety, and tolerability of RBP-7000 with polymers of different molecular weights in individua…
-
CLINICAL_TRIALS research · 2017-01-31Clinical Trial Update: Coronary Artery Disease in Patients Suffering From Schizophrenia [NA]
This entry notes an ongoing clinical trial investigating coronary artery disease in patients with schizophrenia. No phase information or res…
-
CLINICAL_TRIALS trial_result · 2017-01-27Clinical Trial Update: A Multicenter Study of NAP (AL-108) in Schizophrenia [Phase 2]
Phase 2 multicenter study evaluating NAP (AL-108) in schizophrenia completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-01-27Clinical Trial Update: Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia [Phase 4]
Phase 4 clinical trial evaluating the effects of varenicline on smoking lapse in smokers with and without schizophrenia. The study status is…